What investment strategy does Lauxera Capital Partners focus on?

Lauxera Capital Partners focuses on Growth strategies in the private equity space.

How many portfolio companies does Lauxera Capital Partners have?

Lauxera Capital Partners has 15 active portfolio companies and 1 completed exit and 2 funds tracked on GP Intel.

Where is Lauxera Capital Partners headquartered?

Lauxera Capital Partners is headquartered in Paris, France.

What is Lauxera Capital Partners's assets under management?

Lauxera Capital Partners manages approximately €780M in assets under management.

When was Lauxera Capital Partners founded?

Lauxera Capital Partners was founded in 2020.

What sectors does Lauxera Capital Partners invest in?

Lauxera Capital Partners invests across Healthcare, Software.

What are Lauxera Capital Partners's recent exits?

Recent realized exits by Lauxera Capital Partners include: OrganOx (2025) to Terumo Corporation.

Home/GPs/Lauxera Capital Partners

DetailCard

Lauxera Capital Partners

Paris, France·Founded 2020·

Growth Equity

·lauxera.com

Paris-based healthcare growth-equity firm founded January 2020 specializing in European medtech, biotech and HealthTech scale-ups; deploys EUR 780M across Lauxera Growth I (vintage 2022 EUR 260M) and Lauxera Growth II (vintage 2025 EUR 520M oversubscribed hard cap of EUR 500M) with offices in Paris (41 Avenue de Friedland) and San Francisco (Mill Valley CA); notable exit OrganOx to Terumo USD 1.5bn October 2025.

AUM

€780M

Funds

vintages 2022–2025

Portfolio

Exits

Lauxera Capital Partners is a Paris growth equity firm with €780M AUM, 15 active companies and 1 exit.

SectorsHealthcare Software

Key takeaways

·Top sector focus: HealthTech (38% of portfolio).
·Fund cadence: ~3Y between vintages · last raise 2025.

Sector breakdown

16 companies

HealthTech

6 · 38%

MedTech

5 · 31%

Biotech

3 · 19%

Healthcare

1 · 6%

Industrials

1 · 6%

Geography breakdown

8 geographies

France

4 · 25%

Germany

3 · 19%

Sweden

3 · 19%

2 · 13%

Slovenia

1 · 6%

Netherlands

1 · 6%

Denmark

1 · 6%

Key facts

HQParis, France

Founded2020

Websitelauxera.com

Recent exits

Lauxera Capital Partners sold OrganOx to Terumo Corporation in 2025 after 3 years.

Coverage notes

2 funds tracked, 16 portfolio companies (15 active · 1 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Lauxera Capital Partners has raised, with its portfolio companies. Hand-checked from public filings.

2 funds

Fund

Strategy

Vintage

Size

Assets

Exits

Lauxera Growth II

Growth2025€520M4 assets

Growth

2025 · 1yr

€520M

–

Unrealized

4 held

Company	Entry
Acandis MedTech · Germany	2024
Antaros Medical Biotech · Sweden	2025
Bridge to Life MedTech · US	2026
GenePlanet Biotech · Slovenia	2026

Lauxera Growth I

Growth2022€260M11 assets1 exits

Growth

2022 · 4yr

€260M

Unrealized

11 held

Company	Entry
BioLamina Biotech · Sweden	2023
Caresyntax HealthTech · Germany	2023
Lifen HealthTech · France	2021
Lumicks Healthcare · Netherlands	2022
Matrix One HealthTech · Germany	2023
Natural Cycles HealthTech · Sweden	2024
Ospi HealthTech · France	2024
Reapplix MedTech · Denmark	2023
Synovo Group HealthTech · France	2023
Veranex MedTech · US	2022
Verdot Industrials · France	2022

Realized

1 exit

Company	Entry	Exit	Type	Buyer	MOIC
OrganOx MedTech · UK	2022	2025	Trade Sale	Terumo Corporation	–

About Lauxera Capital Partners

Lauxera Capital Partners is a Paris-based healthcare growth equity firm with €660 million of assets under management as of December 2024, founded in January 2020. The firm specialises in European medtech, biotech and HealthTech scale-ups, deploying capital across Lauxera Growth I (vintage 2022, €260M) and Lauxera Growth II (vintage 2025, €400M) with selective offshore exposure to North American healthcare opportunities.

Investment thesis

Lauxera targets European healthcare growth equity in profitable medtech, biotech and HealthTech scale-ups, with equity tickets typically ranging from €20 million to €60 million per transaction. The growth equity mandate enables Lauxera to back profitable healthcare businesses seeking expansion capital rather than early-stage venture exposure, with the healthcare-exclusive focus providing clinical and regulatory expertise across portfolio companies.

Recent activity

Recent realised exits include OrganOx (healthcare, 2025), reflecting selective distribution activity across the healthcare growth portfolio. The platform tracks 2 funds and 13 active portfolio companies across the healthcare-exclusive programme.

Frequently asked questions

What investment strategy does Lauxera Capital Partners focus on?: Lauxera Capital Partners focuses on Growth strategies in the private equity space.
How many portfolio companies does Lauxera Capital Partners have?: Lauxera Capital Partners has 15 active portfolio companies and 1 completed exit and 2 funds tracked on GP Intel.
Where is Lauxera Capital Partners headquartered?: Lauxera Capital Partners is headquartered in Paris, France.
What is Lauxera Capital Partners's assets under management?: Lauxera Capital Partners manages approximately €780M in assets under management.
When was Lauxera Capital Partners founded?: Lauxera Capital Partners was founded in 2020.
What sectors does Lauxera Capital Partners invest in?: Lauxera Capital Partners invests across Healthcare, Software.
What are Lauxera Capital Partners's recent exits?: Recent realized exits by Lauxera Capital Partners include: OrganOx (2025) to Terumo Corporation.